Agenus Pre-Tax Profit Margin 2010-2022 | AGEN

Agenus pre-tax profit margin from 2010 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Agenus Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2022-03-31 $0.31B $-0.03B -8.39%
2021-12-31 $0.30B $-0.03B -9.80%
2021-09-30 $0.31B $0.00B 0.33%
2021-06-30 $0.07B $-0.23B -330.43%
2021-03-31 $0.09B $-0.19B -225.88%
2020-12-31 $0.09B $-0.18B -207.95%
2020-09-30 $0.09B $-0.18B -191.30%
2020-06-30 $0.10B $-0.17B -175.26%
2020-03-31 $0.09B $-0.17B -202.33%
2019-12-31 $0.15B $-0.11B -74.17%
2019-09-30 $0.12B $-0.13B -106.56%
2019-06-30 $0.12B $-0.12B -102.61%
2019-03-31 $0.12B $-0.09B -79.13%
2018-12-31 $0.04B $-0.16B -437.84%
2018-09-30 $0.04B $-0.15B -379.49%
2018-06-30 $0.03B $-0.15B -520.69%
2018-03-31 $0.02B $-0.16B -929.41%
2017-12-31 $0.04B $-0.12B -288.10%
2017-09-30 $0.04B $-0.11B -280.00%
2017-06-30 $0.04B $-0.12B -282.93%
2017-03-31 $0.04B $-0.11B -254.55%
2016-12-31 $0.02B $-0.13B -552.17%
2016-09-30 $0.03B $-0.12B -488.00%
2016-06-30 $0.03B $-0.09B -335.71%
2016-03-31 $0.03B $-0.11B -392.59%
2015-12-31 $0.03B $-0.09B -372.00%
2015-09-30 $0.02B $-0.10B -515.79%
2015-06-30 $0.01B $-0.09B -664.29%
2015-03-31 $0.01B $-0.06B -554.55%
2014-12-31 $0.01B $-0.04B -525.00%
2014-09-30 $0.01B $-0.02B -366.67%
2014-06-30 $0.01B $-0.02B -420.00%
2014-03-31 $0.00B $-0.02B -800.00%
2013-12-31 $0.00B $-0.03B -1000.00%
2013-09-30 $0.00B $-0.03B -725.00%
2013-06-30 $0.00B $-0.03B -700.00%
2013-03-31 $0.00B $-0.02B -600.00%
2012-12-31 $0.02B $-0.01B -68.75%
2012-09-30 $0.02B $-0.01B -75.00%
2012-06-30 $0.02B $-0.01B -75.00%
2012-03-31 $0.02B $-0.01B -68.75%
2011-12-31 $0.00B $-0.02B -600.00%
2011-09-30 $0.00B $-0.02B -500.00%
2011-06-30 $0.00B $-0.02B -500.00%
2011-03-31 $0.00B $-0.02B -475.00%
2010-12-31 $0.00B $-0.02B -550.00%
2010-09-30 $0.00B $-0.02B -450.00%
2010-06-30 $0.00B $-0.02B -575.00%
2010-03-31 $0.00B $-0.03B -750.00%
2009-12-31 $0.00B $-0.03B -750.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.390B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00